Publications by authors named "Stefano Memoli"
Pharmacokinetic evaluation of fezolinetant for the treatment of vasomotor symptoms caused by menopause.
Expert Opin Drug Metab Toxicol
October 2024
Article Synopsis
- Vasomotor symptoms (VMS) affect many menopausal women and can negatively impact their quality of life, with available treatments like menopausal hormone therapy (MHT) posing risks for some.
- Fezolinetant is a newly approved oral non-hormonal drug that targets neurokinin 3 receptors to help alleviate moderate to severe VMS and has demonstrated effectiveness in clinical trials.
- The drug appears to improve VMS-related issues such as sleep and overall quality of life while maintaining a safe profile, highlighting its potential as a key option for women unable to use hormone therapy, although further research is needed.
Genitourinary syndrome of menopause is a comprehensive term that groups genital, urinary and sexual signs and symptoms mainly due sex hormone deficiency and aging, with a crucial impact on quality of life of midlife women. While this broad definition captures the common underlying physiopathology and the frequent overlap of symptomatology, improving knowledge about different components of genitourinary syndrome of menopause may be relevant for individualized treatment, with possible implications for efficacy, compliance and satisfaction. This narrative review focuses on the vulvar component of genitourinary syndrome of menopause, highlighting anatomical and functional peculiarities of the vulva that are responsible for some of the self-reported symptoms, as well as specific signs at physical examination.
View Article and Find Full Text PDF